Intrexon Corp (NYSE:XON)‘s stock had its “buy” rating restated by equities research analysts at Stifel Nicolaus in a report released on Tuesday, April 4th. They currently have a $57.00 price objective on the biotechnology company’s stock. Stifel Nicolaus’ target price points to a potential upside of 169.76% from the stock’s previous close.
Several other equities research analysts have also recently commented on XON. Northland Securities assumed coverage on Intrexon Corp in a research note on Thursday, December 29th. They issued an “outperform” rating and a $40.00 target price for the company. JMP Securities set a $42.00 price target on Intrexon Corp and gave the stock a “buy” rating in a research report on Friday, February 3rd. Finally, Wunderlich reduced their target price on Intrexon Corp from $50.00 to $35.00 and set a “buy” rating on the stock in a report on Tuesday, March 14th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $40.96.
Shares of Intrexon Corp (NYSE:XON) traded down 0.05% during trading on Tuesday, reaching $21.13. 492,185 shares of the company’s stock traded hands. Intrexon Corp has a 1-year low of $18.41 and a 1-year high of $32.90. The company has a 50 day moving average price of $20.10 and a 200 day moving average price of $24.18. The stock’s market capitalization is $2.51 billion.
Intrexon Corp (NYSE:XON) last released its earnings results on Wednesday, March 1st. The biotechnology company reported ($0.37) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by $0.14. The firm earned $46 million during the quarter, compared to analyst estimates of $52.53 million. Intrexon Corp had a negative net margin of 93.97% and a negative return on equity of 18.46%. The firm’s quarterly revenue was up 10.8% on a year-over-year basis. During the same period last year, the business posted ($0.28) earnings per share. On average, equities analysts forecast that Intrexon Corp will post ($0.89) EPS for the current fiscal year.
Several hedge funds have recently added to or reduced their stakes in XON. Third Security LLC acquired a new position in shares of Intrexon Corp during the fourth quarter worth $1,510,708,000. Norges Bank acquired a new position in shares of Intrexon Corp during the fourth quarter worth $17,300,000. Frontier Capital Management Co. LLC increased its position in shares of Intrexon Corp by 540.5% in the fourth quarter. Frontier Capital Management Co. LLC now owns 619,411 shares of the biotechnology company’s stock worth $15,052,000 after buying an additional 522,700 shares during the period. Lagoda Investment Management L.P. acquired a new position in shares of Intrexon Corp during the third quarter worth $13,455,000. Finally, Michael & Susan Dell Foundation acquired a new position in shares of Intrexon Corp during the fourth quarter worth $10,519,000. 84.51% of the stock is currently owned by institutional investors and hedge funds.
Intrexon Corp Company Profile
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Receive News & Ratings for Intrexon Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corp and related companies with our FREE daily email newsletter.